Finder makes money from featured partners, but editorial opinions are our own. Advertiser Disclosure
Acorda Therapeutics Inc is a drug manufacturers-specialty & generic business based in the US. Acorda Therapeutics shares (ACOR) are listed on the NASDAQ and all prices are listed in US Dollars. Acorda Therapeutics employs 118 staff and has a trailing 12-month revenue of around 0.00.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
| Latest market close | $0.48 |
|---|---|
| 52-week range | $0.28 - $6.36 |
| 50-day moving average | $0.72 |
| 200-day moving average | $2.26 |
| Wall St. target price | $10.00 |
| PE ratio | N/A |
| Dividend yield | $0 (0%) |
| Earnings per share (TTM) | $-8.22 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $0.48 from 2022-07-01
| 1 week (2022-06-29) | 7.43% |
|---|---|
| 1 month (2022-06-06) | 55.09% |
| 3 months (2022-04-06) | -70.91% |
| 6 months (2022-01-06) | -79.66% |
| 1 year (2021-07-06) | -89.54% |
|---|---|
| 2 years (2020-07-06) | -35.40% |
| 3 years (2019-07-05) | 7.36 |
| 5 years (2017-07-05) | 20.5 |
Valuing Acorda Therapeutics stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Acorda Therapeutics's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Acorda Therapeutics's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 0.51. A low ratio can be interpreted as meaning the shares offer better value, while a higher ratio can be interpreted as meaning the shares offer worse value.
The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Acorda Therapeutics's future profitability. By accounting for growth, it could also help you if you're comparing the share prices of multiple high-growth companies.
| Revenue TTM | $122.7 million |
|---|---|
| Gross profit TTM | $78.5 million |
| Return on assets TTM | -7.6% |
| Return on equity TTM | -56.93% |
| Profit margin | -77.42% |
| Book value | $9.61 |
| Market capitalisation | $11.3 million |
TTM: trailing 12 months
We're not expecting Acorda Therapeutics to pay a dividend over the next 12 months.
Acorda Therapeutics's shares were split on a 1:6 basis on 3 January 2021. So if you had owned 6 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Acorda Therapeutics shares – just the quantity. However, indirectly, the new 500% higher share price could have impacted the market appetite for Acorda Therapeutics shares which in turn could have impacted Acorda Therapeutics's share price.
Over the last 12 months, Acorda Therapeutics's shares have ranged in value from as little as $0.28 up to $6.36. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Acorda Therapeutics's is 0.4982. This would suggest that Acorda Therapeutics's shares are less volatile than average (for this exchange).
Acorda Therapeutics, Inc. , a biopharmaceutical company, develops and commercializes therapies for neurological disorders in the United States. The company markets Ampyra (dalfampridine), an oral drug to improve walking in patients with multiple sclerosis (MS); and Inbrija for the treatment of OFF periods in Parkinson's disease in Europe. It also markets Ampyra as Fampyra in Europe, Asia, and the Americas. In addition, the company develops ARCUS product for the treatment of acute migrain; rHIgM22, which has completed Phase I clinical trial for the treatment of MS; and Cimaglermin alfa for heart failure patients. The company has collaboration and license agreement with Biogen Inc. for the development and commercialization of Ampyra.
Everything we know about the Citrine Global IPO, plus information on how to buy in.
Everything we know about the Genelux Corporation IPO, plus information on how to buy in.
Everything we know about the Magic Empire Global IPO, plus information on how to buy in.
Everything we know about the Intchains Group IPO, plus information on how to buy in.
Everything we know about the Biostage IPO, plus information on how to buy in.
Everything we know about the Wang & Lee Group IPO, plus information on how to buy in.
Everything we know about the OptMed IPO, plus information on how to buy in.
Everything we know about the Lichen China IPO, plus information on how to buy in.
Everything we know about the LeeWay Services IPO, plus information on how to buy in.
Everything we know about the Nano Labs IPO, plus information on how to buy in.